Literature DB >> 7516823

Structural studies of the O-polysaccharide from the lipopolysaccharide of Moraxella (Branhamella) catarrhalis serotype A (strain ATCC 25238).

P Edebrink1, P E Jansson, M M Rahman, G Widmalm, T Holme, M Rahman, A Weintraub.   

Abstract

The polysaccharide of the Moraxella (Branhamella) catarrhalis serotype A lipopolysaccharide was prepared by mild acid hydrolysis followed by gel permeation chromatography. The structure was established by methylation analysis, mass spectrometry, and NMR spectroscopy. It is concluded that the O-antigenic polysaccharide has the following structure. [formula see text] Methylation analysis of the intact lipopolysaccharide showed that the lipid A portion consisted of 6-substituted glucosamine residues. Methylation followed by methanolysis showed that two Kdo residues were present, one terminal and one 4,5-substituted residue. A terminal Kdo thus substitutes the branch-point Kdo in the 4-position.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516823     DOI: 10.1016/0008-6215(94)80040-5

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  27 in total

1.  Multiplex PCR assay that identifies the major lipooligosaccharide serotype expressed by Moraxella catarrhalis clinical isolates.

Authors:  Katie J Edwards; Johanna M Schwingel; Anup K Datta; Anthony A Campagnari
Journal:  J Clin Microbiol       Date:  2005-12       Impact factor: 5.948

2.  Identification of two late acyltransferase genes responsible for lipid A biosynthesis in Moraxella catarrhalis.

Authors:  Song Gao; Daxin Peng; Wenhong Zhang; Artur Muszyński; Russell W Carlson; Xin-Xing Gu
Journal:  FEBS J       Date:  2008-09-13       Impact factor: 5.542

3.  Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.

Authors:  X X Gu; J Chen; S J Barenkamp; J B Robbins; C M Tsai; D J Lim; J Battey
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

4.  Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.

Authors:  Katie J Edwards; Simon Allen; Bradford W Gibson; Anthony A Campagnari
Journal:  J Bacteriol       Date:  2005-05       Impact factor: 3.490

Review 5.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

6.  Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.

Authors:  Shengqing Yu; Xin-Xing Gu
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

7.  Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.

Authors:  M Rahman; T Holme; I Jönsson; A Krook
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

8.  The tetrasaccharide L-alpha-D-heptose1-->2-L-alpha-D-heptose1--> 3-L-alpha-D-heptose1-->(3-deoxy-D-manno-octulosonic acid) and phosphate in lipid A define the conserved epitope in Haemophilus lipopolysaccharides recognized by a monoclonal antibody.

Authors:  S Borrelli; O Hegedus; D H Shaw; P E Jansson; A A Lindberg
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Late acyltransferase genes lpxX and lpxL jointly contribute to the biological activities of Moraxella catarrhalis.

Authors:  Song Gao; Dabin Ren; Daxin Peng; Wenhong Zhang; Artur Muszyński; Russell W Carlson; Xin-Xing Gu
Journal:  J Med Microbiol       Date:  2013-03-08       Impact factor: 2.472

10.  Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies.

Authors:  Johanna M Schwingel; Katie J Edwards; Andrew D Cox; Hussein Masoud; James C Richards; Frank St Michael; Carmen D Tekwe; Sanjay Sethi; Timothy F Murphy; Anthony A Campagnari
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.